| pubmed-article:18510661 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0025266 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0032952 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0678009 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C0585333 | lld:lifeskim |
| pubmed-article:18510661 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:18510661 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18510661 | pubmed:dateCreated | 2008-8-12 | lld:pubmed |
| pubmed-article:18510661 | pubmed:abstractText | To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed. | lld:pubmed |
| pubmed-article:18510661 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18510661 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18510661 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18510661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18510661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18510661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18510661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18510661 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18510661 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18510661 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18510661 | pubmed:issn | 1464-410X | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:Canadian... | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:PerrottePaulP | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:WinquistEricE | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:ErnstScottS | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:SaadFredF | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:ChengTinaT | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:KarakiewiczPi... | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:NorthScottS | lld:pubmed |
| pubmed-article:18510661 | pubmed:author | pubmed-author:RuetherDeanD | lld:pubmed |
| pubmed-article:18510661 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18510661 | pubmed:day | 5 | lld:pubmed |
| pubmed-article:18510661 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:18510661 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18510661 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18510661 | pubmed:pagination | 551-5 | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:meshHeading | pubmed-meshheading:18510661... | lld:pubmed |
| pubmed-article:18510661 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18510661 | pubmed:articleTitle | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. | lld:pubmed |
| pubmed-article:18510661 | pubmed:affiliation | University of Montreal Hospital Centre, Montreal, PQ, Canada. fred.saad.chum@ssss.gouv.qc.ca | lld:pubmed |
| pubmed-article:18510661 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18510661 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18510661 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:18510661 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
